OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, has announced the expansion of Rhenium-SCT® (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital the latest to come on board. This marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country..

OncoBeta®是一家专注于创新表皮放射性同位素治疗的领先医疗器械公司，它宣布在意大利扩大铼SCT®（皮肤癌治疗）治疗服务，Bolzano医院是最新加入的一家。这标志着国内非黑色素瘤皮肤癌（NMSC）治疗方案的可用性取得了重大进展。。

Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4.

铼皮肤癌疗法是一种先进的放射性核素疗法，可提供无痛，*1,2单次治疗，†1-3非侵入性‡1治疗，无需破坏疤痕。1,4铼SCT治疗采用表面应用含有β发射颗粒的糊剂直接覆盖NMSC病变，靶向癌细胞而无需手术。

Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, 'I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology.'

Bolzano医院的Mohsen Farsad博士对铼SCT设备印象深刻，他指出，“我已经在意大利这里治疗了几名患者，看到了令人印象深刻的结果，并且对设备技术的设计感到满意。”

'Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT,' adds Dr. Farsad.

“铼皮肤癌疗法满足了许多患者对非手术替代治疗NMSCs的愿望，特别是在难以定位的情况下。Farsad博士补充道：“我很高兴继续治疗合适的铼SCT患者。”。

Shannon D. Brown III, CCO at OncoBeta, says, 'While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption.'.

OncoBeta首席财务官香农·D·布朗三世（ShannonD.BrownIII）说，“虽然手术干预仍然是NMSC治疗的标准治疗方法，但往往会导致不理想的结果。铼SCT提供了一种非手术替代方案，可以简单地直接应用于需要治疗的区域，并允许患者在最小程度上恢复日常活动。”。

According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6.

根据GLOBOCAN的估计，2022年至2045年期间，意大利新发NMSC病例数预计将从29000例增加到41700例。欧洲的流行病学数据显示，NMSC的年发病率为每10万名男性129.3例，每10万名女性90.8例。基底细胞癌（BCC）约占意大利所有诊断癌症的15%，每10万居民每年发病率约为100例。

Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, 'Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs.'

OncoBeta医学主任Gerhard Dahlhoff博士强调，“铼SCT能够在保留邻近健康组织的同时，对NMSCs进行靶向、非侵入性治疗。这种对患者友好的方法强调了我们致力于为受NMSC影响的患者提供更多的治疗选择。”

Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.

铼SCT目前在德国、奥地利、瑞士、意大利、西班牙、英国、南非和澳大利亚上市。OncoBeta的分销合作伙伴DSD Pharma将为Bolzano医院的患者提供铼SCT。

About the Rhenium-SCT® (Skin Cancer Therapy)

关于铼SCT®（皮肤癌治疗）

Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4

The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers).

铼SCT是一种无痛，*1,2单次，†1-3非侵入性‡1疗法，即使在其他情况下也被认为难以治疗，也能提供美学效果。1,4,7铼SCT利用放射性同位素铼-188在表皮应用中具有最佳特性，可用于治疗NMSCs（非黑色素瘤皮肤癌）。

The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician.

铼SCT是一种精确的个性化治疗方法，仅适用于治疗所需的区域，而不影响健康组织。4,7专门设计的装置确保铼SCT化合物从不与患者皮肤直接接触，应用医生安全简单。

Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8.

大多数NMSCs病例（基底细胞癌和鳞状细胞癌）可以使用铼SCT一次性治疗。†1-4治疗后病变区域的无瘢痕愈合和健康组织的再生通常在治疗后几周内发生[1,7,8]。

About OncoBeta®

OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs.

OncoBeta®总部位于德国慕尼黑附近的加兴，是一家私营医疗器械公司，专门从事最先进的创新疗法的开发和商业化。自成立以来，OncoBeta一直致力于针对NMSC的表皮放射性同位素疗法铼SCT®（皮肤癌疗法）的开发，监管批准和商业化。

OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards..

OncoBeta根据所有健康、安全和环保监管标准完善了定制的应用程序和设备管理系统。。

Find out more about the Rhenium-SCT at www.oncobeta.com

有关铼SCT的更多信息，请访问www.oncobeta.com

Follow us on social media:

在社交媒体上关注我们：

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

Facebook: https://www.facebook.com/oncobeta/

Facebook: https://www.facebook.com/oncobeta/

Instagram: https://www.instagram.com/oncobeta_gmbh/

Instagram: https://www.instagram.com/oncobeta_gmbh/

About DSD Pharma

关于DSD Pharma

DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient..

DSD Pharma是核医学和放射性药物领域诊断、治疗和放射性药物/医疗设备的分销商。DSD Pharma为客户提供在研究前沿共同开发的产品组合。这确保了HCP最新技术的安全性，并为患者提供了最佳的诊断/治疗/治疗。。

Find out more about DSD Pharma at www.dsd-pharma.com

有关DSD Pharma的更多信息，请访问www.DSD-Pharma.com

Forward-looking statements

前瞻性声明

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information.

本公告包括涉及风险、不确定性和其他因素的前瞻性陈述，其中许多因素不在OncoBeta的控制范围内，可能导致实际结果与前瞻性陈述中讨论的结果产生重大差异。前瞻性声明包括关于OncoBeta计划、目标、目标、未来事件、绩效和/或其他非历史信息的声明。

All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law..

所有此类前瞻性声明均由这些警示声明以及可能伴随前瞻性声明的任何其他警示声明明确限定。OncoBeta没有义务公开更新或修订前瞻性声明，以反映制定日期后的后续事件或情况，除非法律要求。。

*No reported pain during procedure.1,2

*手术过程中没有报告疼痛

†Complete tumour regression in 98.5% of lesions treated.3

‡A treatment is considered non-invasive when no cut or break in the skin is created.9

‡当皮肤没有切口或破裂时，治疗被认为是非侵入性的。9

References

参考文献

Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.

Castellucci P等人，Eur J Nucl Med Mol成像。2021年；48:1511-1521。

Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.

Cipriani C等人，J.皮肤病治疗。2022年；33（2）：969-975。EPUB 2020年7月22日。

Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Cipriani C等人，《治疗性核医学》。2014年。RP Baum（编辑），纽约：斯普林格。

Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.

Tietze JK等人，《临床核医学》，2023年；48:869-76。

Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.

全球疾病负担癌症合作，等。JAMA Oncol。2019年；5（12）：1749-1768年。

Sordi E, et al. Epidemiologia. 2024;5:1–10.

Sordi E等，流行病学。2024;5:1–10.

Cipriani C, et al. International J Nucl Med. 2017; July:114–112.

Cipriani C，et al.International J Nucl Med.2017；July:114-112。

Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.

Sedda AF等人，《临床实验皮肤病学》。2008;33(6):745–749.

Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).

澳大利亚治疗用品管理局。首字母缩略词和术语表。网址：https://www.tga.gov.au/resources/acronyms-and-glossary-terms.（2024年6月访问）。

Contact:

联系人：

Jane Morey

简·莫雷

***@moreymedia.com.au

***@moreymedia.com.au

Source: prnewswire.com

来源：prnewswire.com